About The Longevity Fund
The Longevity Fund is a venture capital firm founded in 2011. It is primarily based out of San Francisco, United States. As of Jan 2022, The Longevity Fund has invested in 17 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Consumer. Most recently it participated in the $***** Series C round of Life Biosciences Overall, The Longevity Fund portfolio has seen 3 IPOs and 1 acquisition including key companies like ALX Oncology, Precision BioSciences and Decibel Therapeutics. A lot of funds co-invest with The Longevity Fund, with names like Khosla Ventures sharing a substantial percentage of its portfolio. The Longevity Fund has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
The Longevity Fund's List of Top Investments
The Longevity Fund has a portfolio of 17 companies. Their most notable investments are in Spring and Loyal.Their portfolio spans across United States and Canada. They have invested in Life Sciences, HealthTech, Consumer and 7 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by The Longevity Fund:Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.
Key facts about Life Biosciences
- Founded Year: 2017
- Location: Boston (United States)
- Stage: Series D
- Total Funding till date: $261M
- Employee Count: 26 as on Mar 31, 2026
- Investors: Globalive Capital, LeFrak and 12 Others
- Latest Funding Round: Series D, Apr 08, 2026, $*****
- Highlight: Editors' Pick
Developer of therapeutics for age-related diseases. The company uses propriety technology includes the ALEMBIC that focuses on developing medicines to combat biological aging by targeting pathologic cells like senescent ones that drive age-related diseases.
Key facts about RUBEDO LIFE SCIENCES
- Founded Year: 2018
- Location: Sunnyvale (United States)
- Stage: Series A
- Total Funding till date: $52M
- Employee Count: 36 as on Mar 31, 2026
- Investors: Khosla Ventures, The Longevity Fund and 11 Others
- Latest Funding Round: Series A, Apr 22, 2024, $*****
- Highlight: Editors' Pick
_1549346058109.png?format=webp&height=120&width=120){kind=logo}
3. ALX Oncology
Developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.
Key facts about ALX Oncology
- Founded Year: 2015
- Location: Burlingame (United States)
- Annual Revenue: $1.18M as on Dec 31, 2020
- Stage: Public
- Total Funding till date: $123M
- Employee Count: 59 as on Mar 31, 2026
- Investors: BVF Partners, Cormorant Asset Management and 10 Others
- Latest Funding Round: Series C, Feb 12, 2020, $*****
- Highlight: Public
4. Loyal
Provider of therapeutics for the treatment of dogs health. It offers LOY-002 forthe treatment of metabolic dysfunction in large dogs, LOY-001, and LOY-003 for crrecting overexpression of IGF-1 and growth hormone (GH) in large dogs.
Key facts about Loyal
- Founded Year: 2020
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $250M
- Employee Count: 205 as on Mar 31, 2026
- Investors: Bain Capital Ventures, Baillie Gifford and 17 Others
- Latest Funding Round: Series C, Feb 11, 2026, $*****
- Highlight: Editors' Pick
_1578289648591.png?format=webp&height=120&width=120){kind=logo}
5. Epirium Bio
Epirium Bio is a developer of therapeutic solutions for the treatment of cancer patients. It is developing viral immunotherapies that promote mitochondrial biogenesis and function. The company is developing for cancer patients. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function.
Key facts about Epirium Bio
- Founded Year: 2008
- Location: San Diego (United States)
- Stage: Series A
- Total Funding till date: $85M
- Employee Count: 13 as on Mar 31, 2026
- Investors: Adams Street Partners, Longitude Capital and 5 Others
- Latest Funding Round: Series A, Dec 18, 2019, $*****
- Highlight: Editors' Pick
The Longevity Fund's Year-on-Year Investment Trends
The Longevity Fund has invested in 17 companies over the last 12 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Life Biosciences and most recent follow-on round was in Loyal.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
2021 | 3 | 1 | 4 |
2020 | 2 | 1 | 3 |
2019 | 2 | 0 | 2 |
2018 | 4 | 1 | 5 |
The Longevity Fund's Investments by Stage
The Longevity Fund has made 6 investments in Seed stage with an average round size of $6.76M, 5 investments in Series A stage with an average round size of $31.6M and 3 investments in Series C stage with an average round size of $64M.Stage of entry | No. of Investments |
|---|---|
Seed | 6 |
Series A | 5 |
Series C | 3 |
Note: We have considered here, only first round of investments
The Longevity Fund's Investments by Sector
The Longevity Fund has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Consumer, Enterprise Applications and Healthcare. Notably, it has invested in 15 Tech companies, 14 Enterprise (B2B) companies, 4 Software companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
HealthTech | 4 |
Consumer | 2 |
Enterprise Applications | 2 |
Healthcare | 2 |
Others | 8 |
Note: We have considered here, only first round of investments
The Longevity Fund's Investments by Geography
The Longevity Fund has made most investments in United States (13), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 13 |
Canada | 1 |
Note: We have considered here, only first round of investments
The Longevity Fund's recent investments
The Longevity Fund has not made any investment in 2026 so far.Here are the most recent investments by The Longevity Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 06, 2022 | United States | Series C | 1288 | ||
Dec 14, 2021 | Canada | Series A | 1212 | ||
Jul 21, 2021 | United States | Seed | 8102 | [+8] | |
Jun 23, 2021 | United States | Series A | 9204 | [+4] | |
Apr 22, 2021 | United States | Series A | 8961 | [+11] |
IPOs and Publicly Listed companies in The Longevity Fund's Portfolio
3 of The Longevity Fund's portfolio companies have become public. Metacrine got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2020 at marketcap of $85M and ALX Oncology got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are The Longevity Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 15, 2020 | - | - | 2276 | |
Jul 17, 2020 | - | - | 6200 | |
Mar 28, 2019 | May 12, 2015 | Series A | 3428 |
_1549346058109.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in The Longevity Fund's Portfolio
1 company from The Longevity Fund's portfolio has been acquired. The most recent acquisition was Decibel Therapeutics in Aug 2023 by Regeneron Pharmaceuticals for $*****.Here are The Longevity Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 10, 2023 | Jun 19, 2018 | Series C | 9253 |
Team profile of The Longevity Fund
The Longevity Fund has a team of 2 members including 1 Partner and 1 Principal located in United States. The Longevity Fund's team does not sit on the board of any company as of now.Co-investors of The Longevity Fund
Over the past 12 years, 143 investors have co-invested in The Longevity Fund's portfolio companies. This includes funds and angels.
- Invested before The Longevity Fund: National Science Foundation, NIST and 25 others have invested in rounds before The Longevity Fund. There is 1 company where National Science Foundation has invested before The Longevity Fund and 1 company where NIST has invested before The Longevity Fund.
- Top Co-investors of The Longevity Fund: 66 investors entered a company along with The Longevity Fund. These include investors like Khosla Ventures (2 companies).
- Invested after The Longevity Fund: A total of 50 investors have invested in The Longevity Fund's portfolio after their investments. Top Investors include Brace Pharma Capital (2 companies), Ahren (1 company) and Hevolution (1 company).
Recent News related to The Longevity Fund
•
Loyal Raises $100M Series C to Advance First Canine Longevity DrugPet Age•Feb 12, 2026•Loyal, age1, The Longevity Fund, Baillie Gifford
•
age1 Launches to Advance The Longevity Fund’s Mission to Extend Healthy LifespanBusiness Wire•Sep 19, 2023•age1, The Longevity Fund
•
•
A startup working on extending dogs' lives just raised $27MThe Business Journals•Sep 30, 2021•Hexagon Bio, Highnote, Loyal, The Longevity Fund and 4 others
•
Cake Raises $3.7M to in FundingFinSMEs•Jul 22, 2021•Cake, AARP, Inhealth Ventures, Two Lanterns Advisory and 6 others
•
•
Edifice Health Raises $12M in FundingFinSMEs•Apr 26, 2021•Edifice Health, Leaps by Bayer, Paladin Capital, Vertical Venture Partners and 11 others
•
Rubedo Life Sciences Closes $12M Seed Financing RoundFinSMEs•Dec 07, 2020•RUBEDO LIFE SCIENCES, Khosla Ventures, The Longevity Fund, Refactor Capital and 1 other
•
•
